|Titre :||Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? (2001)|
|Auteurs :||V. D. HOPE ; A. JUDD ; M. HICKMAN|
|Type de document :||Article : Périodique|
|Dans :||American Journal of Public Health (Vol.91, n°1, January 2001)|
|Article en page(s) :||38-42|
|Discipline :||MAL (Maladies infectieuses / Infectious diseases)|
Thésaurus TOXIBASEHEPATITE ; PREVALENCE ; ENQUETE ; VOIE INTRAVEINEUSE ; REDUCTION DES RISQUES
OBJECTIVES: This study sought to establish the prevalence of hepatitis C antibodies (anti-HCV) and hepatitis B antibodies (anti-HBc) among injection drug users in England and Wales.
METHODS: A voluntary cross-sectional survey collected oral fluid samples and behavioral information; 2203 injectors were recruited through drug agencies, and 758 were recruited in the community.
RESULTS: Prevalence was 30% for anti-HCV, 21% for anti-HBc, and 0.9% for HIV antibodies. Anti-HCV prevalence rates were significantly greater among those with longer injecting careers, those in older age groups, those residing in London, those recruited in drug agencies, those positive for anti-HBc, and those with a previous voluntary HIV test.
CONCLUSIONS: Anti-HCV prevalence rates among injectors in England and Wales, where comprehensive harm reduction programs exist, are lower than rates in other industrialized countries.
|Domaine :||Drogues illicites / Illicit drugs|
|Refs biblio. :||32|
|Affiliation :||Public Health Laboratory Service, Communicable Disease Surveillance Centre, London, UK|
|Centre Emetteur :||13 OFDT|